nemu

  1. HOME
  2. Portfolio

Portfolio

Deep pipeline of novel compounds, each with the potential to be first or best-in-class treatments for unmet patient needs

AskAt’s strategy centers on utilizing this global, integrated collaboration network to continually add value to each of its candidate programs.

Out-licensed Programs

Program Disease Discovery Non-Clinical Clinical Registration Launch Region of Develop.
(Sales)		 Development
Company
Phase 1 Phase 2 Phase 3
Program Indication Phase Development
Region		 Partner
AAT-007 EP4 antagonist Cancer
Ongoing
P1 Ongoing China NewBay
Pain
Completed
P1 Completed China 3DM
Pain/Inflammation
(Animal)
Launched
Launched (JP, US, EU,& Others) Elanco
AAT-008 EP4 antagonist Cancer
Completed
(P1-IND approved)
Non-clin. Completed
(P1-IND approved) 		China NewBay
AAT-076 COX-2 inhibito Pain
Ongoing
P1 Ongoing China 3DM
Pain
Completed
Non-clin. Completed Outside Japan&China Noitami
Pain/Inflammation
(Animal)
Ongoing
Non-clin. Completed US Velo-1
AAT-730 CB2 agonist Pain
Ongoing
P1 Ongoing UK OCT

In-house Development and Business Development Programs

Program Disease Discovery Non-Clinical Clinical Area Of License
Phase 1 Phase 2 Phase 3
Program Indication Phase Area Of License
AAT-007 EP4 antagonist Cancer
P1b Completed
P1b Completed All except for China
AAT-008 EP4 antagonist Cancer
Completed
Non-clin. Completed All except for China
Pain/Inflammation (Animal)
Completed
Non-clin. Completed All
AAT-009 5-HT4
partial agonist 		Dementia
Completed (US)
P1 Completed
(US) 		All
Cognitive
Impairment (Animal)
Completed
Discovery
Completed 		All
AAT-076 COX-2 inhibitor Pain
P2a Completed (US, Acute Pain)
P2a Completed
(US, Acute Pain) 		Japan
AAT-730 CB2 agonist Pain & Neuronal
Diseases
Completed
Discovery
Completed 		Japan
Pain/Inflammation
(Animal)
Completed
Discovery
Completed 		All

PAGE TOP

Menu